dacarbazine has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Imano, M; Kawashima, K; Nishida, S; Obata, N; Satou, T; Tabata, M; Takeda, T; Tsubaki, M | 1 |
1 other study(ies) available for dacarbazine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Article | Year |
---|---|
Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Fluvastatin; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Melanoma, Experimental; Mice, Inbred C57BL; Signal Transduction; Simvastatin; Skin Neoplasms; Tumor Burden | 2019 |